Market News & Trends
Avacta & Oncosec to Collaborate on Innovative Gene Delivery
Avacta & Oncosec to Collaborate on Innovative Gene Delivery Avacta Group plc and OncoSec Medical Incorporated recently announced they have entered into a research collaboration…
BioCryst & Idera Announce Merger to Combine Capabilities
BioCryst Pharmaceuticals, Inc. and Idera Pharmaceuticals, Inc. recently announced they have signed a definitive merger agreement to form a new enterprise focused on the development…
Biolog Announces Mitochondrial Assay Breakthrough
Biolog, Inc. recently announced the launch of a new product line that enables a comprehensive scan of mitochondrial function. Better technology for measuring mitochondrial function…
PPD & Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug Development
Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), and Quotient Sciences (Quotient), a drug development services organization, recently announced a new…
Marina Biotech Announces Drug Development & Licensing Agreement With Autotelic Bio
Marina Biotech, Inc. recently announced it has entered into a binding agreement with Autotelic Bio Inc., to enter into a license of Marina’s IT-103 clinical…
Avacta Group Announces Positive Outcome of Proof-of-Concept Study
Avacta Group plc recently announced its initial study with Glythera Limited, the developer of next-generation antibody drug conjugates, has concluded successfully. Following this study, the…
OWKIN Closes $11-Million Financing for AI in Drug Development
OWKIN, a predictive analytics company that utilizes transfer learning to accelerate drug discovery and development, recently announced an $11-million Series A funding round, led by…
RedHill Biopharma Announces Final Results from Phase II Study
RedHill Biopharma Ltd. recently announced top-line final results from the Phase II clinical study with BEKINDA 12 mg (RHB-102) for the treatment of diarrhea-predominant irritable…
Colorcon Transforms the Sugar Coating Process With a New Opadry System
Colorcon Inc. recently announces an exciting process development for sugar coated pharmaceutical tablets with the launch of Opadry® SGR, Rapid Sugar Film Coating System. This…
Sanofi to Acquire Bioverativ for $11.6 Billion
Sanofi and Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders, have entered into a definitive agreement under which…
Next Breath Announces Injectable Extractable & Leachable Services
Next Breath, a division of AptarGroup, is pleased to announce the extension of their cGMP analytical services to include development services for injectable delivery systems,…
CTI BioPharma to Receive $10-Million Milestone
CTI BioPharma recently announced that it expects to receive a $10-million milestone payment in February 2018 from Teva Pharmaceutical Industries related to the achievement of…
Pandion Therapeutics Announces $58-Million Financing to Advance Tissue-Specific Immune Modulator Drugs
Pandion Therapeutics, Inc. recently announced the completion of a $58-million Series A financing. This funding will be used to advance its initial drug programs for…
Syndax Announces Clinical Collaboration With Genentech
Syndax Pharmaceuticals Inc. recently announced a new clinical collaboration with Genentech, a member of the Roche Group. As part of the collaboration, the two companies…
ARCA Biopharma Announces Completion of GENETIC-AF Phase 2B Clinical Trial
ARCA Biopharma, Inc. recently announced the completion of patient follow-up for GENETIC-AF, a Phase 2B, double-blind, superiority clinical trial evaluating Gencaro (bucindolol hydrochloride) as a…
Teneobio Announces Strategic Alliance With TESARO
Teneobio, Inc., a next-generation multi-specific antibody therapeutics company, recently announced the initiation of a research collaboration and licensing agreement with TESARO, Inc., an oncology-focused biopharmaceutical…
ProQR & Galapagos Announce Research Collaboration
ProQR Therapeutics N.V. recently announced it has entered into a research collaboration agreement with Galapagos N.V. Under the agreement, the two companies will work together…
CymaBay Therapeutics Receives $5-Million Milestone Payment
CymaBay Therapeutics, Inc. recently announced it has received a $5-million milestone payment from Kowa Pharmaceuticals America for the initiation of a study evaluating the pharmacokinetics…
NANOBIOTIX Partners With the Providence Cancer Institute
Nanobiotix recently announced it will begin a preclinical collaboration with Providence Cancer Institute to study Nanobiotix's lead product, NBTXR3, a first-in-class nanoparticle designed for direct…
Achaogen Announces FDA Acceptance of New Drug Application With Priority Review
Achaogen, Inc. recently announced the US FDA has accepted for review the company’s New Drug Application (NDA) for plazomicin for the treatment of complicated urinary…
